New acetylcholinesterase inhibitors for alzheimer's disease

Mona Mehta, Abdu Adem, Marwan Sabbagh

Research output: Contribution to journalArticlepeer-review

290 Citations (Scopus)

Abstract

Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.

Original languageEnglish
Article number728983
JournalInternational Journal of Alzheimer's Disease
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Ageing
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience
  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'New acetylcholinesterase inhibitors for alzheimer's disease'. Together they form a unique fingerprint.

Cite this